Ron Squarer

Mr. Squarer brings more than 30 years of proven leadership in oncology drug development and commercialization to the Nuvalent Board. Most recently, he served as the Board Chair of Deciphera Pharmaceuticals, which was acquired by Ono Pharmaceuticals in 2024. He also served as the Chief Executive Officer of Array Biopharma, where he oversaw the research, development, and successful commercialization of several oncology treatments, as well as the 2019 acquisition of the company by Pfizer. Prior to Array, Mr. Squarer held positions of increasing responsibility with Hospira, a global pharmaceutical and medical device company. Earlier in his career, he served as Senior Vice President of Global Corporate and Business Development at Mayne Pharma and held leadership roles at Pfizer and SmithKline Beecham Pharmaceuticals in the U.S. and Europe.

Mr. Squarer currently serves as the Board Chair of ADC Therapeutics and as a Board member at Travere Therapeutics. Mr. Squarer earned an MBA. from the Kellogg School of Management, Northwestern University, and a bachelor’s degree in biochemistry from the University of California, Berkeley.